Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA1-/2- carriers.
Parameswaran Grace Luther LalitkumarParameswaran G LalitkumarLaura GarciaSuby Jo VargheseJoseph W CarlsonKristina Gemzell-DanielssonAngelique F RådestadPublished in: Acta obstetricia et gynecologica Scandinavica (2018)
Our study showed an anti-proliferative effect on ovarian BRCA1-/2- MSC on in vitro combined treatment with mifepristone and progesterone. These findings suggest that mifepristone or other selective progesterone receptor modulators could be developed as a preventive treatment and postpone early use of prophylactic salpingo-oophorectomy as well as reduce the risk of ovarian cancer.